World Multiple Sclerosis Day, Jack Osbourne, in partnership with Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), kicked off the third year of the You Don’t Know Jack About MS® campaign to raise awareness about multiple sclerosis (MS) in the United States and provide valuable resources to the MS community. In response to the evolving needs of the community, You Don’t Know Jack About MS® launched an enhanced online destination featuring new content, resources, and docu-series chronicling Jack’s journey with relapsing-remitting MS designed to help MS patients, caregivers and loved ones learn how to navigate through diagnosis and living with the disease.
“I have a personal interest in developing the new You Don’t Know Jack About MS® website to make it as helpful and relatable as possible for those living with MS, like myself,” Osbourne said. “Since my diagnosis three years ago, I have found so much satisfaction in helping others better understand MS, and I hope the new content inspires others who are living with MS to take an active role in how they manage their disease.”
You Don’t Know Jack About MS® was created by Jack and Teva to dispel myths and misperceptions about MS, and does so by sharing stories of patients and advocates. Inspired by Jack, the son of Ozzy and Sharon Osbourne, the new website features an online video docu-series chronicling Jack’s journey with MS, downloadable tools and resources, and a blog in which Jack shares his personal experience living with MS. Beyond showcasing Jack’s personal journey, the video docu-series, available on www.YouDontKnowJackAboutMS.com, spotlights others living with MS and their caregivers. In the latest webisode, “Driving the MS Conversation,” Jack surprises three MS patients in a taxi cab to learn more about their lives and share their experiences to help others with the disease.
In addition, the site offers information and tools designed to help MS patients navigate and understand the different stages of MS, from diagnosis to managing the disease effectively. Comprehensive educational content is featured from a prominent U.S. advocacy group, the Multiple Sclerosis Association of America (MSAA), including information on how MS works inside the body and tips on how to talk to family, friends and children about the condition.
“Living with MS can be challenging at times, so it’s important that people with MS have access to relatable and reliable information,” said Peter Damiri, Vice President of Programs and Services, MSAA. “MSAA’s mission is to improve lives today for the entire MS community and we applaud Jack for his openness and commitment to raising awareness for this disease. MSAA is proud to partner with Jack and Teva and provide our educational content for the You Don’t Know Jack About MS® program.”
Further You Don’t Know Jack About MS® activities planned in 2015 include the unveiling of two additional webisodes, and blog posts from Jack broaching topics such as fitness and diet, stress management and how he plans to discuss his disease with his daughter. Guest bloggers, including medical experts and Jack’s mother,Sharon Osbourne, will contribute posts on their perspectives, to add breadth to the impact of MS. (Original Source)
Shares of Teva closed yesterday at $59.94 . TEVA has a 1-year high of $68.75 and a 1-year low of $47.36. The stock’s 50-day moving average is $62.27 and its 200-day moving average is $58.63.
On the ratings front, Teva has been the subject of a number of recent research reports. In a report issued on April 30, Oppenheimer analyst Akiva Felt maintained a Buy rating on TEVA, with a price target of $77, which implies an upside of 28.5% from current levels. Separately, on April 29, Standpoint Research’s Ronnie Moas upgraded the stock to Buy and has a price target of $80.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Akiva Felt and Ronnie Moas have a total average return of 32.5% and 9.2% respectively. Felt has a success rate of 64.6% and is ranked #32 out of 3607 analysts, while Moas has a success rate of 72.6% and is ranked #21.
In total, one research analyst has assigned a Hold rating and 7 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $72.29 which is 20.6% above where the stock closed yesterday.
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.